{"entity":{"id":"nct07610941","kind":"trial","name":"Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies","aka":[],"tldr":"A phase 1 trial of MST-0312 run by Mestag Therapeutics Limited, now recruiting.","summary":"Phase 1 Open Label Trial of MST-0312 Alone and in Combination in Subjects With Solid Malignancies is a phase 1 interventional study registered as NCT07610941 by Mestag Therapeutics Limited, with 157 participants planned, started 2026-04-09. Conditions recorded: Cancer-Neoplasms. Interventions recorded: MST-0312 and Pembrolizumab.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07610941","url":"https://clinicaltrials.gov/study/NCT07610941"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["mst-0312"],"companies":["mestag-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07610941","phase":"1","setting":"A Multi-arm, Open-label, Phase 1 Trial to Evaluate the Safety and Tolerability, Pharmacokinetics and Anti-tumour Activity of MST-0312 When Given Alone and in Combination With Anticancer Treatments in Subjects With Solid Malignancies","sponsor":"Mestag Therapeutics Limited","enrolled":157,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07610941/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"mst-0312","kind":"drug","name":"MST-0312","route":"/drugs/mst-0312/"}],"company":[{"id":"mestag-therapeutics","kind":"company","name":"Mestag Therapeutics","route":"/companies/mestag-therapeutics/"}]}}